PO119 IMMUNE REACTIVITY IN PATIENTS WITH BREAST CANCER ASSOCIATED WITH TYPE 2 DIABETES MELLITUS

Introduction: It is well known that course of metastatic disease is influenced by different parameters than primary breast cancer. In that context the prognosis of metastatic breast cancer patients is not easily predicted. Aim of this study was to determine the influence of selected biomarkers on different time dependent sequences of follow up i.e. relapse-free survival (RFS) and overall survival (OS) in metastatic breast cancer. Material and Methods: This study included 109 metastatic breast cancer patients with visceral/nonvisceral involvement (median age 50 years) with known clinicopathological characteristics. HER2, Topo2a and c-myc amplification was determined by chromogenic in situ hybridization (CISH) on the same paraffin embedded primary tumor samples. Different types of chemotherapy and/or endocrine therapy were administered to the majority of the women in adjuvant and metastatic setting. RFS was defined as time from diagnosis till appearance of metastatic disease and OS was defined as time from diagnosis till death. RFS and OS were estimated using the Kaplan Meier method and survival differencies were compared with the log-rank test. P value less than 0,05 was considered as statistically significant. Results: Only HER2 amplification was predictive for RFS 24 months, whereas Topo2a amplification, as well as estrogen receptor and progesterone receptor status were associated with OS (5 year survival) (p=0,001, p=0,012 and p=0,003, respectively). Amplification of c-myc was not relevant neither for RFS and OS. In addition, among clinicopathological parameters, nodal status, the number of lymph nodes at the time of diagnosis and tumor size were relevant for RFS